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Available online 20 May 2016Cephalosporins, particularly cefepime, exert neurotoxic side effects that can lead to status epilepticus. These neu-
rotoxic side effects include myoclonus, dystonic movements, tremor, asterixis, seizure, status epilepticus, en-
cephalopathy, and sometimes coma. Status epilepticus, particularly nonconvulsive status epilepticus (NCSE), is
a well-known but unusual complication in patients with altered renal function who were receiving treatment
with intravenous cephalosporins, especially cefepime. We reviewed the clinical and electroencephalographic
(EEG) characteristics of 7 patients with renal failure who developed consciousness alterations with changes in
EEG activitywhile being treatedwith cephalosporins. All patients developed renal failure: six patients had chron-
ic renal failure, one patient had acute renal failure, and two patients were administered hemodialysis.
Nonconvulsive status epilepticus was observed between 2 and 8 days (average of 5.6 days) after initiation of
cephalosporins. Cephalosporins are epileptogenic drugs, especially when used in excessive doses or when
renal function is impaired. Critically ill patients with chronic kidney disease are particularly susceptible to cefe-
pimeneurotoxicity. Clinical and electrophysiological results of patients guide the diagnosis of NCSE by healthcare
providers.
© 2016 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Treatment1. Introduction
Cephalosporins are characterized by a broad antimicrobial spectrum
and excellent tissue penetration in clinical practice [1]. They are
currently among the most widely used lactam antibiotics for the treat-
ment of serious gram-negative infections. Cephalosporins are grouped
into “generations” according to their antimicrobial properties: the ﬁrst-
generation cephalosporins include cefazolin, the second-generation
cephalosporins include cefuroxime, the third-generation cephalosporins
include ceftazidime, and the fourth-generation cephalosporins include
cefepime. Cefepime is often used as the ﬁrst choice for the treatment of
severe infections. Cephalosporins, particularly cefepime, have neurotoxic
side effects that can lead to status epilepticus [2,3]. Neurotoxic side effects
due to cephalosporins include myoclonus, dystonic movements, tremor,
asterixis, seizure, status epilepticus, encephalopathy, and sometimes
coma [4]. Status epilepticus, particularly nonconvulsive status epilepticus
(NCSE), is a well-known but unusual complication in patients with
altered renal function who are receiving treatment with intravenous
cephalosporins, especially cefepime [4]. Nonconvulsive status epilepticus90 224 4429177.
, bora@uludag.edu.tr (I. Bora),
en access article under the CC BY-NC(NCSE) is a condition that may be associated with different levels of
altered consciousness without any apparent motor signs. Patients with
NCSE exhibit continuous or intermittent electrographic discharges
detected by electroencephalography (EEG) [5]. Electroencephalograph-
ic recording is crucial for recognizing NCSE. A delay in diagnosis and
treatment may be associated with increased mortality or neuronal
loss, as well as impaired cognitive and behavioral abilities [6]. Discon-
tinuation of the drug often leads to restoration of neurological function.
Nonconvulsive status epilepticus is a rare complication of cephalosporin
therapy, with only a few isolated cases reported in the literature.
We reviewed the clinical and electroencephalographic characteris-
tics of 7 patients with renal failure who developed consciousness
alterations and changes in EEG activity while being treated with cepha-
losporins, particularly cefepime.
1.1. Case 1
The ﬁrst case is ES, a 52-year-old man undergoing hemodialysis for
the past 4 years because of stage-III chronic renal insufﬁciency second-
ary to focal segmental glomerulosclerosis. Hewas seen in the nephrolo-
gy clinic because of a progressive decline in mental status, delirium,
agitation, disorientation, and difﬁculty with cooperation sometimes
accompanied by myoclonic jerks. His medical history included hyperten-
sion and diabetes mellitus for the past 20 years. He presented with high
fever and positive blood cultures for Staphylococcus aureus and was-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
24 I. Bora et al. / Epilepsy & Behavior Case Reports 6 (2016) 23–27diagnosed with a urinary tract infection. The patient was initially admin-
istered cefazolin at 4 g/day; cefazolin was eventually discontinued, and
cefepime treatment was started at 2 g every 12 h. A progressive deterio-
ration in mental status, including delirium, agitation, disorientation, and
difﬁculty in cooperating, developed on the second day of cefepime treat-
ment. Neurologic examination revealed no focal neurological deﬁcits.
Magnetic resonance imaging of the brain showed atrophy in the right
temporo-occipital junction reﬂecting the sequelae of an old infarction of
1.5 × 2 cm. Electroencephalography revealed continuous 2- to 3-Hz gen-
eralized bi/triphasic sharp waves, which led to a diagnosis of NCSE. Cefe-
pime treatment was discontinued, and 10 mg of diazepam was
administered via intravenous injection. Clinical symptoms and EEG ﬁnd-
ings improved approximately 7 days after discontinuation of cefepime
(Fig. 1).
1.2. Case 2
The second case is GK, a 39-year-old woman with ankylosing spon-
dylitis, amyloidosis, and chronic renal failure. She was admitted to the
orthopedic clinic because of septic arthritis. Drainage was performed,
and treatment with cefepime at 3 g/day was initiated. On the sixth
day of cefepime treatment, the patient suddenly stopped speaking and
exhibited loss of orientation, increased agitation, occasional laughing,
meaningless speech, and progressive impairment of consciousness.
Myoclonic jerks were also observed. On the neurological exam, we ob-
served that the patient was confused. Her speech was not meaningful,
and shewasmoving all of her extremities in response to painful stimuli.
No focal neurological signs or meningismus was present. Laboratory
tests revealed a creatinine level of 6.51mg/dl with a BUN concentration
of 56mg/dl. The Hgb level was 8.2. The platelet count was 185,000, and
the Ca++ level was 7.9. Cranial MR imaging and LP analysis were nor-
mal. An assessment of EEG activity demonstrated continuous, rhythmic,
generalized triphasic 2- to 3-Hz sharp-wave activity. Cefepime was
discontinued, and Targocid treatment (400 mg) was initiated twice aFig. 1. First electroencephalogram showing continuous, genday. Diazepam was administered intravenously. Clinical symptoms
and EEG ﬁndings improved approximately 5 days after discontinuation
of cefepime and administration of diazepam. Electroencephalography
demonstrated generalized theta- and delta-wave activity (Fig. 2).
1.3. Case 3
The third case is KI, a 24-year-oldwomanwhowas being followed in
clinic for chronic renal failure due to lupus nephritis and a 3-year history
of hemodialysis. Renal transplantation was performed in September of
2014. Tacrolimus and mycophenolate treatments were initiated after
transplantation. Ceftriaxone at 2 g/day was initiated to treat recurrent
urinary tract infections. The patient deteriorated on the third day of
treatment and presented with three generalized tonic–clonic seizures
on the same day. Her consciousness did not improve after the seizures.
On neurological examination, the patient was confused and couldmove
her limbs only in response to painful stimuli. The blood level of tacroli-
muswasmeasured andwaswithin normal limits. The results of a crani-
al MRI were normal, and there was no indication of an acute infarct.
Electroencephalographic activity was characterized by continuous,
rhythmic, generalized 2- to 3-Hz sharp-wave activity. Extensive epilep-
tiform activity was also observed in her EEG results. Ceftriaxone was
discontinued. Signs and symptoms of NCSE decreased after diazepam
treatment and an infusion of phenytoin; symptoms continued todecline
as this treatment paradigmwasmaintained. Clinical symptoms and EEG
abnormalities improved approximately 3 days after discontinuation of
ceftriaxone.
1.4. Case 4
The fourth case is VK, a 58-year-old woman who was hospitalized
because of chronic renal failure accompanied by mesothelioma, diabe-
tes mellitus, coronary artery disease, and bronchopneumonia. Cefepime
was initiated at 4 g/day to treat the bronchopneumonia. On the eightheralized, rhythmic sharp- and slow-wave discharges.
Fig. 2. EEG showing generalized theta- and delta-wave activity after treatment with diazepam.
25I. Bora et al. / Epilepsy & Behavior Case Reports 6 (2016) 23–27day of treatment, the patient became less responsive and was unable to
speak. No other neurological signs were observed. Laboratory analyses
revealed a creatinine level of 4.67 mg/dl with a BUN concentration of
161mg/dl. A cranialMRI was normal. Electroencephalography detected
continuous, rhythmic, generalized 2- to 3-Hz sharp-wave activity that
was compatible with a diagnosis of NCSE. Cefepime therapy was
discontinued, and the status treatment protocol was applied. Five days
after discontinuing cefepime treatment, clinical and neurophysiological
ﬁndings began to normalize.
1.5. Case 5
The ﬁfth case is IC, a 68-year-old male patient with prostate cancer
and a femoral fracture associated with bone metastases and chronic
renal failure. Hewas hospitalized and he developed pneumonia and os-
teomyelitis after an operation. Cefepime at 4 g/day and amoxicillin at
1000mg/daywere initiated. The patient became disoriented and exhib-
ited difﬁculty with cooperation, agitation, meaningless speech, and in-
somnia on the fourth day of cefepime and amoxicillin treatment. His
neurological exam revealed no other neurological signs apart from con-
fusion and disorientation. The patient's right leg was stable because of
the recent operation. Laboratory tests demonstrated a creatinine level
of 4.0 mg/dl and a BUN level of 167 mg/dl. The results of cranial MR im-
aging were normal. Electroencephalographic activity was indicative of
NCSE. Cefepime therapy was discontinued, the status treatment
protocol was applied, and diazepam was administered intravenously.
Remission of his neuropsychological and clinical ﬁndings was observed
on the ﬁfth day after discontinuation of cefepime. Electroencephalo-
graphic recordings revealed diffuse slow-wave activity and triphasic
sharp-wave activity.
1.6. Case 6
The sixth case is ZA, a 74-year-old female patient whowas admitted
because of rheumatoid arthritis and ankylosing spondylitis. Thepatient's pulmonologist initiated treatment for pneumonia with cefe-
pime at 4 g/day. The patient exhibited an altered mental state; she be-
came unresponsive, and myoclonus was observed in both arms on the
fourth day of cefepime treatment. The results of her neurological
exam were normal except for difﬁculty with cooperation and disorien-
tation. Magnetic resonance imaging of the brain was normal. Electroen-
cephalography showed continuous, rhythmic, generalized 2- to 3-Hz
sharp-wave activity. Cefepime was discontinued after the ﬁrst EEG,
and diazepam and levetiracetam were administered intravenously.
Five days after discontinuing cefepime therapy, her mental state
returned to normal, and she became alert and oriented. Her neurophys-
iological ﬁndings declined, and her EEG results gradually fully im-
proved. On the 7th day of treatment, these results had completely
normalized.
1.7. Case 7
The seventh case is BA, a 71-year-old man with hepatic carcinoma
who developed high fever and elevated urea and creatinine levels
after anoperation. Ceftriaxonewas initiated at 2 g/day to treat a possible
wound infection. On the 5th day of antibiotic treatment, NCSEwas iden-
tiﬁed in the patient because of meaningless speech, an inability to walk,
sleepiness, and abnormal EEG ﬁndings. Ceftriaxone treatment was ter-
minated, and diazepam treatment was initiated. After 5 days, apparent
neurophysiological and clinical impairments were recorded. Electroen-
cephalography revealed diffuse slow-wave activity after ceftriaxone
withdrawal.
2. Results
We describe 7 patients (4 females and 3 males) who developed
NCSE while receiving intravenous cephalosporins. The mean age of
the patients was 55.1 years (ranging from 24 to 74). Five patients
were administered cefepime, and 2 patients received ceftriaxone during
NCSE. All patients had developed renal failure: six patients had chronic
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26 I. Bora et al. / Epilepsy & Behavior Case Reports 6 (2016) 23–27renal failure, one had acute renal failure, and two underwent hemodial-
ysis. The doses of cephalosporins, particularly cefepime, were adjusted
for renal failure. The doses of cephalosporins (cefepime, ceftriaxone,
cefazolin) ranged from2 to 4 g/day. Nonconvulsive status epilepticus la-
tency, the period between the start of cefepime treatment and detection
of neurological deterioration, was between 2 and 8 days, and the aver-
age latency was 5.6 days.
Patients exhibited symptoms such as a progressive decline inmental
status, disorientation, and agitation, sometimes associatedwithmild fa-
cial or limb myoclonus. Electroencephalography showed continuous or
intermittent bursts of generalized, high-voltage, 2- to 3-Hz sharp- and
slow-wave activity. Intravenous diazepam completely suppressed epi-
leptiform activity in all patients when cephalosporins were withdrawn
and intravenous antiepileptic therapy was started in all patients. Patient
outcomes were good after discontinuation of cephalosporins and initia-
tion of anticonvulsant treatments. Neurologic symptoms disappeared fol-
lowingwithdrawal of cephalosporin therapy. Theﬁrst signs of clinical and
neurophysiological improvement were observed after 3 to 7 days. Sum-
maries of the 7 cases are presented in Table 1.
3. Discussion
Some antimicrobial agents (penicillins, cephalosporins, carbapenems,
quinolones, and antimalarials) may precipitate seizures even in patients
who do not have epilepsy. Patients with renal failure or a previous diag-
nosis of epilepsy are most susceptible to the toxic effects of cephalospo-
rins [7]. Cephalosporins are epileptogenic drugs, especially when used
at excessive doses or when renal function is impaired [8]. Critically ill pa-
tientswith chronic kidney disease are particularly susceptible to cefepime
neurotoxicity. Neurotoxicity from cephalosporinsmay vary from enceph-
alopathy to NCSE [4]. Risk factors for cephalosporin-induced neurotoxici-
ty include renal insufﬁciency, excessive dose usage (particularly
cefepime), andpreexisting CNS abnormalities [9,10]. Latency in the devel-
opment of neurotoxicity varied from one to ten days. All reported neuro-
logical symptoms typically resolved within two to seven days after
discontinuation of the cephalosporin [4,11–13]. In our patients, the num-
ber of days between the start of cefepime treatment and the emergence of
neurological deterioration was between 2 and 8 days, with an average
time period of 5.6 days.We observed improvement in neurological symp-
toms after 3-7 days of antibiotic withdrawal. Electroencephalographic re-
sults are critical for a correct diagnosis of cephalosporin neurotoxicity,
particularly NCSE. Neurotoxicity is seen more often in elderly patients,
who may have age-related declines in creatinine clearance. Neurotoxic
effects in patients with renal insufﬁciency are due to altered pharmacoki-
netics resulting in increased circulating cephalosporin concentrations
[14]. All of our patients exhibited chronic or acute renal failure, but
three of them were younger adults, not elderly adults. Nonconvulsive
status epilepticus can be seen as a complication of cephalosporin therapy
even at therapeutic doses and in the presence of normal renal function
and normal creatinine clearance. This may be particularly true in the
elderly. However, it can also occur in young people. Nonconvulsive status
epilepticus can be difﬁcult to recognize in elderly patients, particularly in
patients with no history of seizures. None of our patients reported a
previous history of seizures. If the blood–brain barrier is disrupted, as in
cases of uremia, drugs can more easily cross the BBB, inducing CNS
toxicity that is believed to cause NCSE [7].
The mechanism of neurotoxicity in cephalosporin therapy involves
inhibiting GABA-A release, increasing glutamate levels, and inducing
release of endotoxins and TNF-alpha, which is involved in septic
encephalopathy [15–17].
Diagnosis of drug-induced NCSE has increased in recent years and
diagnosis should be considered in all patients with unexpected changes
in mental status during treatment with intravenous cephalosporins,
particularly in patients with some degree of renal dysfunction. Urgent
EEG should be considered. Electroencephalography is essential to
guide prompt and accurate diagnosis. In all patients in the current
27I. Bora et al. / Epilepsy & Behavior Case Reports 6 (2016) 23–27study, NCSE was diagnosed through EEG activity and clinical ﬁndings. It
is difﬁcult to distinguish NCSE from metabolic encephalopathy unless
an EEG is obtained [18].
Electroencephalographic and clinical improvement after intravenous
diazepam, phenytoin, or levetiracetam treatment indicate that the diag-
nosis of NCSE was accurate. Early detection and diagnosis are important
in this potentially reversible condition as prolonged delays in diagnosis
may result in increased morbidity or mortality [19]. Electroencephalo-
graphic activity demonstrated continuous, generalized, high-voltage,
rhythmic bi/triphasic 2- to 3-Hz sharp-wave activity in patients with
NCSE. Nonconvulsive status epilepticus did not immediately resolve
with DZP or other AEDs but gradually resolved only after cefepime was
discontinued. Responses to antiepileptic drugs can be delayed in NCSE.
Furthermore, triphasic waves and other EEG alterations of metabolic
origin also may be suppressed by intravenous BZDs.
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